Please complete this form if you are interested in connecting with a staff member at Terns Pharmaceuticals in order to facilitate referral into the CARDINAL clinical trial of eligible patients with previously treated CP-CML.

Once you complete the form a staff member will contact you as soon as possible in order to facilitate the referral of patients to an active clinical trial site near you.

Additional information about this clinical trial can be found here.

Key Inclusion Criteria:

• Male or female participants ≥ 18 years of age at the time of signing the informed consent

• Have an ECOG performance status score of 0 to 2

• Have an established cytopathologically confirmed diagnosis of BCR-ABL1 positive CML in Chronic Phase with or without T315l mutation

• Have received treatment with active site targeting TKIs and have treatment failure, suboptimal response, or treatment intolerance

• Participants who are intolerant of asciminib, and do not have resistant/relapsing disease

• Adequate organ function, as assessed by local laboratory
  
  Key Exclusion Criteria:

• CML in accelerated or blast phase

• Systemic antineoplastic therapy (including prior TKIs, interferon-alfa, therapeutic antibodies, chemotherapy) or other experimental therapy 7 days before the first dose of TERN-701

• Have completed previous anticancer therapy without resolution of all associated clinically significant toxicity (to ≤ Grade 2 or baseline)